Small clinical trials evaluating them head-to-head at different levels of prostate cancer can be desired. This may be accomplished with asymptomatic Adult men which have early Innovative-phase prostate cancer (e.g. PSA > 60 ng/ml); a downward change of PSA could be very easily made use of as a relevant biomarker endpoint in reasonably modest and sm… Read More